Drugs / ANZURSTOBART
ANZURSTOBART
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05168202 | Jan 2022 → Jul 2024 | acute myeloid leukemia, myelodysplastic syndrome | Bristol-Myers Squibb | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT03783403 | Mar 2019 → Aug 2024 | neoplasm | Celgene Corporation | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-05-19 | Bristol-Myers Squibb | Results Bristol Myers Squibb Data at ASCO and EHA 2022 Highlight Progress in Transforming Treatment for Patients with Cancer and Blood Disorders bms.com ↗
Data from Phase 1 studies of CC-99282, a cereblon E3 ligase modulator (CELMoD ® ) agent, and CC-95251, an anti-signal regulatory protein-alpha (SIRPα) antibody combined with rituximab, show promising activity in patients with relapsed or refractory non-Hodgkin lymphoma (EHA). |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-05-19 | Bristol-Myers Squibb | Bristol Myers Squibb Data at ASCO and EHA 2022 Highlight Progress in Transforming Treatment for Patients with Cancer and Blood Disorders bms.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ANZURSTOBART | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095321 ↗ |
| Known as | BMS-986351 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095321 ↗ |
| Known as | CC-95251 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03783403 ↗ |
| Modality | Monoclonal antibody | — CHEMBL5095321 ↗ |